Buparlisib + Sonidegib
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Basal Cell
Conditions
Carcinoma, Basal Cell, Recurrent Skin Cancer, Skin Neoplasms, Basal Cell Nevus Syndrome
Trial Timeline
Feb 1, 2015 → Jun 1, 2017
NCT ID
NCT02303041About Buparlisib + Sonidegib
Buparlisib + Sonidegib is a phase 2 stage product being developed by Novartis for Carcinoma, Basal Cell. The current trial status is terminated. This product is registered under clinical trial identifier NCT02303041. Target conditions include Carcinoma, Basal Cell, Recurrent Skin Cancer, Skin Neoplasms.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02303041 | Phase 2 | Terminated |
Competing Products
20 competing products in Carcinoma, Basal Cell